Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 29INDUSTRY 21NIH 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 49Prostatic Neoplasms 38Carcinoma, Non-Small-Cell Lung 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms 23Multiple Myeloma 22Lymphoma 21Leukemia, Myeloid, Acute 17Colorectal Neoplasms 17Melanoma 15Lung Neoplasms 13Hodgkin Disease 11Brain Neoplasms 11Lymphoma, Non-Hodgkin 10Glioblastoma 10Squamous Cell Carcinoma of Head and Neck 9Pancreatic Neoplasms 9Neoplasm Metastasis 9Medulloblastoma 9Leukemia, Biphenotypic, Acute 9Leukemia 9Head and Neck Neoplasms 9HIV Infections 9Neuroblastoma 8Hematologic Neoplasms 8Ependymoma 8Glioma 7Carcinoma, Renal Cell 7Astrocytoma 7Wilms Tumor 6

Interventions

Temozolomide 1Etoposide 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Neuroendocrine × 1 year × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡